



ELSEVIER

Available online at www.sciencedirect.com

SCIENCE @ DIRECT®

Mutation Research xxx (2006) xxx–xxx

MR

Fundamental and Molecular  
Mechanisms of Mutagenesiswww.elsevier.com/locate/molmut  
Community address: www.elsevier.com/locate/mutres

## Loss of Ubr2, an E3 ubiquitin ligase, leads to chromosome fragility and impaired homologous recombinational repair

Yan Ouyang<sup>a</sup>, Yong Tae Kwon<sup>b</sup>, Jee Young An<sup>b</sup>, Danny Eller<sup>a</sup>, Shih-Chang Tsai<sup>a</sup>,  
Silvia Diaz-Perez<sup>a</sup>, Joshua J. Troke<sup>c</sup>, Michael A. Teitell<sup>c</sup>, York Marahrens<sup>a,\*</sup>

<sup>a</sup> Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

<sup>b</sup> Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA

<sup>c</sup> Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

Received 19 October 2005; received in revised form 5 December 2005; accepted 21 December 2005

### Abstract

The N-end rule pathway of protein degradation targets proteins with destabilizing N-terminal residues. Ubr2 is one of the E3 ubiquitin ligases of the mouse N-end rule pathway. We have previously shown that *Ubr2*<sup>-/-</sup> male mice are infertile, owing to the arrest of spermatocytes between the leptotene/zygotene and pachytene of meiosis I, the failure of chromosome pairing, and subsequent apoptosis. Here, we report that mouse fibroblast cells derived from *Ubr2*<sup>-/-</sup> embryos display genome instability. The frequency of chromosomal bridges and micronuclei were much higher in *Ubr2*<sup>-/-</sup> fibroblasts than in +/+ controls. Metaphase chromosome spreads from *Ubr2*<sup>-/-</sup> cells revealed a high incidence of spontaneous chromosomal gaps, indicating chromosomal fragility. These fragile sites were generally replicated late in S phase. *Ubr2*<sup>-/-</sup> cells were hypersensitive to mitomycin C, a DNA cross-linking agent, but displayed normal sensitivity to gamma-irradiation. A reporter assay showed that *Ubr2*<sup>-/-</sup> cells are significantly impaired in the homologous recombination repair of a double strand break. In contrast, *Ubr2*<sup>-/-</sup> cells appeared normal in an assay for non-homologous end joining. Our results therefore unveil the role of the ubiquitin ligase Ubr2 in maintaining genome integrity and in homologous recombination repair.

© 2006 Elsevier B.V. All rights reserved.

**Keywords:** Ubr2 ubiquitin ligase; N-end rule proteolytic pathway; Genome instability; Fragile sites; Homologous recombination repair; Mitomycin C sensitivity

### 1. Introduction

The mouse *Ubr2* gene encodes one of several E3 ubiquitin ligases of the N-end rule pathway for ubiquitin-mediated protein degradation [1–3]. E3 ubiquitin ligases covalently transfer a 76 amino acid ubiquitin polypeptide from an enzyme called E2 to a target protein with

the specificity mainly determined by the E3 ligase [4–6]. In the N-end rule pathway, the N-terminal amino acid determines the half life of the target protein [7] and a particular internal lysine is polyubiquitinated [8,9]. The only known in vivo substrates for *Ubr2* were identified very recently. They are RGS4, RGS5, and RGS16, which function as down-regulators of signaling by specific G proteins [10,11].

Homozygous null mutation of *Ubr2* is embryonic lethal in an inbred 129 background [3], whereas in a mixed 129/B6 background, only female *Ubr2*<sup>-/-</sup> mice display embryonic lethality while *Ubr2*<sup>-/-</sup> males sur-

\* Corresponding author. Tel.: +1 310 267 2466;

fax: +1 310 794 5446.

E-mail address: ymarahrens@mednet.ucla.edu (Y. Marahrens).

vive but are sterile [3]. The overall architecture of *Ubr2*<sup>-/-</sup> testes is normal and spermatogonia are intact [3]. During meiosis I in +/+ mice, the homologous chromosomes align during leptotene and zygotene stages and chromosomal synapsis is complete by the pachytene stage where the homologous chromosomes are joined by synaptonemal complexes. Male *Ubr2*<sup>-/-</sup> sterility is characterized by a defect in homologous pairing during meiosis I and in the death of pachytene stage spermatocytes by apoptosis [3].

Several proteins that are important for meiosis I also play surprisingly diverse roles in the DNA damage response in somatic cells [12], raising the question of whether *Ubr2* is also involved in the DNA damage response. Mice that are deficient in the DNA base mismatch repair (MMR) proteins Pms2 [13] or Mlh1 [12] display defects in chromosome pairing during spermatogenesis. Mice lacking the double strand break (DSB) checkpoint protein kinase ataxia telangiectasia mutated (ATM) are also infertile with spermatocytes arresting at the zygotene/pachytene stage of meiosis I and exhibiting aberrant synapsis with unpaired axial cores [14–17]. Mutations in DNA-PK, a kinase that is essential for non-homologous end joining (NHEJ), cause elevated levels of apoptosis during spermatogenesis [18]. Several proteins that are involved in homologous recombination (HR) repair are also implicated in meiosis I [12] including Rad51, the Rad51 paralogs (Rad51B, Rad51C, Rad51D, XRCC2, and XRCC3), and the cohesin complex (Smc1, Smc3, Scc1, Sa1, and Sa2) [19–21]. Finally, the repair of DNA cross-links involves not only HR repair proteins, but also the Fanconi anemia (FA) genes A, B, C, D2, E, F, G, and L [22,23], BRCA1 [22], BRCA2 [22], and ATR [24]. Male mouse knockouts for FA proteins D2 [25], A [26,27], C [26,28], and G [29] display impaired fertility with defects in axial pairing, synapsis, and an abundance of apoptotic pachytene spermatocytes. BRCA1 [12,30], BRCA2 [12], and ATR [12] are also implicated in male meiosis. A requirement for *Ubr2* in the aforementioned processes of the DNA damage response can be surveyed by assaying *Ubr2*<sup>-/-</sup> cells for sensitivity to particular genotoxic agents, and by direct assays that test the efficacy of specific DNA repair mechanisms.

Here, we investigate whether *Ubr2*<sup>-/-</sup> mouse fibroblasts display spontaneous chromosome instability and fragility. We also test the sensitivity of *Ubr2*<sup>-/-</sup> cells to doxorubicin, IR, and mitomycin C and ask whether the cells have normal levels of HR repair and NHEJ. We report that loss of *Ubr2* results in high incidence of chromosome breaks, a hypersensitivity to mitomycin C, and a severe deficiency in HR DSB repair.

## 2. Materials and methods

### 2.1. Establishment of mouse embryonic fibroblasts and their immortalization

*Ubr2*<sup>-/+</sup> mice of the inbred 129/SvJ background [3] were intercrossed and *Ubr2*<sup>-/-</sup> and +/+ mouse embryonic fibroblasts (MEFs) were prepared from E13.5 mouse embryos from the resulting litters and immortalized using SV40 T-antigen [31]. The PCR primers used for identifying the *Ubr2*<sup>-</sup> and + alleles were UBR2f (5'-CTA CTG CAT GCT GTT TAA TGA TGA G), UBR2r (GGA GGT AGA AAC ATG CAA ATC TCT G), and Neof (5'-CCA GCT CAT TCC TCC CAC TCA TGA TC).

### 2.2. Metaphase chromosome spreads

Log-phase MEFs were treated with 0.3 µg/ml colcemid (Invitrogen Inc., Carlsbad, CA) for 30 min, trypsinized and resuspended in Dulbecco's modified eagle medium (DMEM) with 10% fetal bovine serum, pelleted by centrifugation, resuspended in 1× phosphate buffered saline (PBS), pelleted by centrifugation, and resuspended in 0.4% KCl for 15 min. A half volume of 3:1 methanol:acetic acid solution was then added one drop at a time to the cell suspension. The cells were pelleted by centrifugation, resuspended in 5 ml 3:1 methanol:acetic acid solution, pelleted again by centrifugation, resuspended in a 200 µl of 3:1 methanol:acetic acid solution, and dropped onto glass slides to obtain spreads. Chromosomes were stained with GIEMSA (Invitrogen Inc.) or DAPI (Vysis, Downers Grove, IL).

### 2.3. Assay for late replication

BrdU (30 µM) was added to asynchronous growing MEFs at 80% confluence. It had previously been determined that 4.5 h is the appropriate duration of BrdU incorporation for the late replication timing assay for such immortalized mouse fibroblasts [32]. Subsequent to culturing fibroblasts for 4.5 h in presence of BrdU, 50 ng/ml colcemid (Life Technologies, Grand Island, NE) was added 1 h before harvest. Cell suspensions were incubated in 0.4% KCl at 37 °C for 13–15 min, followed by fixation with 3:1 methanol:acetic acid. Metaphase spreads were prepared by dropping the BrdU-treated cells onto cover slips followed by treatment in 70% formamide/2XSSC (0.3 M sodium chloride, 0.03 M sodium citrate dihydrate, pH 7.0) at 73 °C for 2 min to denature the chromosomes. Spreads were incubated in blocking buffer (1× PBS, 10% fetal bovine serum, 0.2% Tween-20) and the incorporated BrdU was detected using monoclonal anti-BrdU antibody (Sigma, St. Louis, MO) at a 1:20 dilution in blocking solution followed by treatment with a 1:150 dilution of Texas-Red anti-mouse antibody (Jackson ImmunoResearch, Westgrove) in blocking buffer. Images were captured using Quips mFISH software (Vysis), transferred to NIH image (<http://rsb.info.nih.gov/nih-image>), and the number of pixels occupied by the chromosomes bearing the gaps or breaks (DAPI) and by fluorescently labeled

145 BrdU (Texas-Red) on these same chromosomes were then  
146 calculated.

#### 147 2.4. MEF survival following mitomycin C, IR, and 148 doxorubicin treatment

149 To determine the sensitivity of *Ubr2*<sup>-/-</sup> and +/+ MEFs  
150 to IR and mitomycin C, immortalized MEFs were seeded at  
151 1000 cells/10 cm plate. Colonies were counted 7 days sub-  
152 sequent to gamma-irradiation (IR) and 9 days after the ini-  
153 tiation of mitomycin C treatment at the following concen-  
154 trations: 0, 0.2, 0.3, and 0.4 μM. Mitomycin C was main-  
155 tained in the media throughout the experiment. For each IR  
156 or mitomycin C treatment, the post-irradiation survival is  
157 represented as the number of colonies surviving treatment  
158 divided by the number of colonies in the untreated control.  
159 For each condition, averages were calculated from three  
160 plates.

161 To determine the sensitivity of *Ubr2*<sup>-/-</sup> and +/+ MEFs to  
162 doxorubicin, 10<sup>4</sup> cells were plated on to 96-well plates, fol-  
163 lowed by treatment with doxorubicin (10, 50, and 100 ng/ml)  
164 (Sigma). After 3 days, cells were exposed to 0.5 mg/ml  
165 of MTT [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyl tetrazolium  
166 bromide] (Sigma) for 5 h. Media was removed and 0.15 ml of  
167 DMSO was added to each well, followed by incubation at 37 °C  
168 for 5 min. The absorbance was measured at 550 nm. This assay  
169 [33] is based on the ability of a mitochondrial dehydrogenase  
170 enzyme from viable cells to cleave the tetrazolium rings of the  
171 pale yellow MTT and form a dark blue formazan crystal which  
172 is impermeable to cell membranes, thus resulting in its accu-  
173 mulation within healthy cells. The number of surviving cells  
174 is directly proportional to the level of the created formazan  
175 product.

#### 176 2.5. Non-homologous end joining assay

177 pGreenLantern plasmid (BD Biotechnology, Franklin  
178 Lakes, NJ) was linearized by cleavage with *Eco*R1 and *Hind*III  
179 and the completeness (>99%) of cleavage was verified by  
180 agarose gel electrophoresis. Both enzymes cleave between the  
181 CMV promoter and GFP open reading frame (ORF). Transient  
182 transfections were carried out following the Fugene-6 protocol  
183 (Roche Inc., Alameda, CA). Purified linearized DNA (1 μg)  
184 was mixed with 3 μl of Fugene-6 and 100 μl of serum-free  
185 DMEM (Invitrogen), incubated for 15 min at room temper-  
186 ature, and added to 5 × 10<sup>5</sup> log-phase cells in each well of a  
187 six-well plate. Cells were trypsinized 2 days later and subjected  
188 to flow cytometry.

#### 189 2.6. Homologous recombination assay

190 *Ubr2*<sup>-/-</sup> and +/+ cells were transfected with the plasmid  
191 p59xDR-GFP6 [34] using the Fugene-6 transfection reagent  
192 (Roche Inc.) and hygromycin-resistant stable cell lines were  
193 obtained. The intactness of this integrated reporter construct  
194 was determined using PCR. Cell lines carrying intact reporter

195 constructs were transiently transfected with the *I-Sce*I expres-  
196 sion construct pCBASce [34] or with the control plasmid  
197 pBluescript (Stratagene, La Jolla, CA). The plasmid pCAG-  
198 NZE [35] carrying an intact GFP expression construct was  
199 used to test transfection efficiency. Two days after transfection,  
200 cells were subjected to flow cytometry to identify GFP-  
201 expressing cells. Homologous recombination efficiency was  
202 calculated by normalizing the GFP positive cells arising in  
203 pCBASce-transfected or pBluescript-transfected cells to one  
204 control cell line, and the HR efficiency was expressed as a  
205 percentage.

#### 206 2.7. Statistical analyses

207 *P*-values representing the significance of the interac-  
208 tion between *Ubr2* genotype and IR dose, mitomycin C  
209 concentration, or doxorubicin concentration, were obtained  
210 using the General Linear Model in SAS/STAT software  
211 (SAS Institute Inc., Cary, NC). All other statistical anal-  
212 yses were performed using the software package R [36]  
213 which can be downloaded from <http://cran.r-project.org/>. For  
214 the NHEJ and HR repair assays, differences in measure-  
215 ments were tested across categorical groupings using the  
216 Kruskal–Wallis test [37]. For the replication timing analysis,  
217 the *P*-value was obtained using a Binomial test available at  
218 <http://www.herine.net/stat/papers/dbinom.pdf>.

### 219 3. Results

#### 220 3.1. Absence of hypersensitivity to IR or a defect in 221 NHEJ in *Ubr2*<sup>-/-</sup> fibroblasts

222 Somatic cells deficient in DSB cell cycle checkpoints  
223 are hypersensitive to IR [38]. To determine whether  
224 *Ubr2*-deficiency also confers hypersensitivity to IR,  
225 we intercrossed *Ubr2*<sup>-/+</sup> mice of the 129Sv/J inbred  
226 background and identified *Ubr2*<sup>-/-</sup> and +/+ mouse  
227 embryonic fibroblasts using PCR [3] (Fig. 1A). A num-  
228 ber of MEF lines were obtained and exposed to γ-  
229 IR. The *Ubr2*<sup>-/-</sup> MEFs were not significantly more  
230 sensitive to IR than the +/+ cells (*P*=0.435, using a  
231 General Linear Model) (Fig. 1B). This suggested that  
232 *Ubr2* is unlikely to be required for the DSB cell cycle  
233 checkpoint.

234 The normal sensitivity to γ-IR also suggested that  
235 *Ubr2* is unlikely to be required for NHEJ. To verify  
236 that this is the case, we directly tested the ability of  
237 *Ubr2*<sup>-/-</sup> cells to perform NHEJ of double strand breaks  
238 using a plasmid-based assay [39,40]. In this assay, a  
239 double strand break was generated by cleaving a GFP  
240 reporter plasmid (see Section 2) between the GFP ORF  
241 and its promoter, using two enzymes such that the pro-  
242 moter and the ORF of the reporter gene are separated  
243 by incompatible ends (Fig. 1C, top). The NHEJ path-




Fig. 1. *Ubr2*<sup>-/-</sup> cells are not hypersensitive to IR or defective in NHEJ. (A) Identification of *Ubr2*<sup>-/-</sup> and +/+ MEFs using PCR. M, DNA size markers. (B) Survival of *Ubr2*<sup>-/-</sup> (filled symbols) and +/+ (open symbols) MEFs following treatment with  $\gamma$ -IR. Each treatment was done in triplicate and averages and standard deviations are shown. To reduce overlap of the symbols in the charts, the symbols representing different cell lines at the same treatment dosage were slightly horizontally offset. (C) Assay for NHEJ reveals no significant difference between *Ubr2*<sup>-/-</sup> and +/+ cells. Repair of a break with non-homologous DNA ends by NHEJ results in GFP expression. Three *Ubr2*<sup>-/-</sup> and three +/+ cell lines were each subjected to this assay three times and averages and standard deviations are shown.


way would seal the broken ends and allow the reporter construct to express GFP. The +/+ and *Ubr2*<sup>-/-</sup> MEF lines displayed similar levels of GFP expression (Fig. 1C, bottom) that were not significantly different ( $P=0.398$  using the Kruskal–Wallis test [37]). This indicated that the NHEJ pathway is indeed functional in *Ubr2*<sup>-/-</sup> cells.

### 3.2. Genomic instability in *Ubr2*<sup>-/-</sup> cells

Micronuclei are features reported in somatic cells deficient in several DNA damage response proteins including FA [41], BRCA1 [42], ATR [43], and ATM [44]. Nucleoplasmic bridges have been reported in cells from FA patients [41] and in ATM-deficient cells [45,46]. Primary *Ubr2*<sup>-/-</sup> and +/+ fibroblasts from *Ubr2*<sup>+/-</sup> 129/SvJ intercrosses were examined for micronuclei and nucleoplasmic bridges. The scale of these analyses was curtailed by an under-representation of E13.5 *Ubr2*<sup>-/-</sup> embryos in pregnant females and by difficulties in growing primary *Ubr2*<sup>-/-</sup> MEFs. Nevertheless, micronuclei and nucleoplasmic bridges were scored without prior knowledge of which slides were experimental and which slides were the controls. In the absence of exogenous reagents, primary *Ubr2*<sup>-/-</sup> MEFs displayed structures resembling micronuclei in 5 out of 100 cells scored (Fig. 2A), while no unambiguous micronuclei were seen in 100 primary +/+ MEFs examined (not shown). Structures resembling nucleoplasmic bridges were observed in 6 out of 100 untreated primary *Ubr2*<sup>-/-</sup> MEFs (Fig. 2B) and in 0 out of 100 untreated primary +/+ MEFs examined (not shown).

Micronuclei can arise from chromosome breaks [44]. Nucleoplasmic bridges can be the product of

Fig. 2. Evidence of chromosomal fragility in *Ubr2*<sup>-/-</sup> MEFs. (A) Evidence of spontaneous micronuclei (arrows) in primary *Ubr2*<sup>-/-</sup> MEFs. (B) Primary *Ubr2*<sup>-/-</sup> MEF displaying a spontaneous nucleoplasmic bridge possibly consisting of chromosomal material joining two nuclei (arrow). (C) Proportion of metaphase chromosome spreads displaying chromosomal breaks or gaps in three *Ubr2*<sup>-/-</sup> and two +/+ cell lines. (D) Break or gap in one sister chromatid in a metaphase chromosome spread from a *Ubr2*<sup>-/-</sup> MEF (arrow). (E) Breaks or gaps in both sister chromatids in a spread from a *Ubr2*<sup>-/-</sup> MEF (arrow). (F) Diagram of the assay employed to identify late replicating regions on chromosomes: BrdU, red; DAPI, blue. (G and H) Late replication detected at gaps or breaks in an *Ubr2*<sup>-/-</sup> spread from a cell that had been exposed to BrdU while in late S phase. (G) Negative of DAPI stained chromosome reveals gaps or breaks (arrows); DAPI, brown. (H) The chromosomes displaying gaps or breaks shown at higher magnification and displaying fluorescent immunostaining for BrdU (green) that had been incorporated while the cells were in late S phase. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)



276 translocations that give rise to dicentric chromosomes  
 277 [47,48]. The presence of elevated numbers of micronu-  
 278 clei and nucleoplasmic bridges in *Ubr2*<sup>-/-</sup> cells raised  
 279 the possibility that *Ubr2*-deficiency may cause genome

280 fragility in the mouse genome that are a source of these  
 281 defects. Expressed fragile sites can be visualized as  
 282 gaps or breaks in metaphase chromosome spreads. The  
 283 frequency of spontaneous gaps and breaks was deter-

284 mined in spreads from two  $+/+$  and three  $Ubr2^{-/-}$   
 285 cell lines.  $Ubr2^{-/-}$  spreads revealed a substantially  
 286 higher incidence of gaps and breaks than  $+/+$  spreads  
 287 ( $P = 2.2 \times 10^{-16}$  using a Chi-square test) (Fig. 2C). Gaps  
 288 and breaks involving one sister chromatid (Fig. 2D) or  
 289 both sister chromatids at corresponding sites (Fig. 2E)  
 290 were observed, indicating fragility in the  $Ubr2^{-/-}$   
 291 genome.

292 One property associated with fragile sites is late repli-  
 293 cation in S phase [49–52]. To determine whether the  
 294 gaps or breaks in  $Ubr2^{-/-}$  spreads are associated with  
 295 late replicating regions, fibroblasts were subjected to an  
 296 assay for late-replication timing. Unsynchronized expo-  
 297 nentially growing  $Ubr2^{-/-}$  and  $+/+$  cells were exposed  
 298 to BrdU for a 4.5 h interval and then spreads were  
 299 prepared and subjected to fluorescent immunostaining  
 300 for BrdU that had been incorporated into chromosomal  
 301 DNA. Cells that were in late S phase at the time of  
 302 BrdU addition incorporated BrdU in late S phase and  
 303 this was identified on the condensed metaphase chro-  
 304 mosomes using fluorescent immunostaining (Fig. 2F,  
 305 bottom). Cells that were in early- or mid-S phase dur-  
 306 ing the exposure to BrdU failed to reach M phase in  
 307 the 4.5 h interval and consequently were not represented  
 308 among the spreads (Fig. 2F, top). Zero percent ( $n = 25$ )  
 309 of BrdU-labeled  $+/+$  spreads displayed gaps or breaks.  
 310 This frequency is similar to the percent spreads display-  
 311 ing gaps or breaks from cells without BrdU treatment  
 312 (Fig. 2C) indicating that the presence of BrdU had little  
 313 or no effect the frequency of chromosome gaps or breaks.  
 314 Inspection of  $Ubr2^{-/-}$  metaphase chromosome spreads  
 315 displaying BrdU incorporation revealed that 24/30 chro-

316 mosomal gaps or breaks examined were associated with  
 317 late replicating chromosomal regions (Fig. 2G and H).  
 318 The proportion of BrdU was determined for each chro-  
 319 some using NIH image (<http://rsb.info.nih.gov/nihi->  
 320 [image](http://rsb.info.nih.gov/nihi-image)). On an average, 26.4% of the chromosomes  
 321 displayed BrdU signal. A Binomial test was used  
 322 to determine that the co-localization of chromosome  
 323 breaks and BrdU signal was statistically significant  
 324 ( $P = 2.9 \times 10^{-9}$ ).

### 3.3. $Ubr2^{-/-}$ cells do not display resistance to doxorubicin but are hypersensitive to mitomycin C

325 Deficiencies in the MMR genes *PMS2* and *MLH1*  
 326 not only lead to a predisposition to fragile sites after  
 327 treatment with the replication inhibitor aphidicolin [53]  
 328 but also to a hypersensitivity to mitomycin C [54].  
 329 Cells deficient in HR repair genes have been reported  
 330 to show spontaneous chromosome gaps and breaks  
 331 and also a sensitivity to mitomycin C [35,55–64].  
 332 FA cells also display fragility (after aphidicolin treat-  
 333 ment) [65] and a pronounced mitomycin C sensitivity  
 334 [66].  $Ubr2^{-/-}$  cells were much more sensitive to mit-  
 335 omycin C than  $+/+$  cells; this was particularly evident  
 336 when cells were exposed to 0.3  $\mu$ M mitomycin C and  
 337 only  $+/+$  cells survived (Fig. 3A). The General Linear  
 338 Model revealed that this effect was highly significant  
 339 ( $P < 0.0001$ ). The *Ubr2* protein may thus be involved  
 340 in MMR, DSB HR repair, and/or DNA cross-link repair.  
 341

342 Loss or reduction of expression of *MLH1*, *PMS2*,  
 343 and other MMR genes have been linked to an  
 344  
 345




Fig. 3. Survival of  $Ubr2^{-/-}$  and  $+/+$  MEFs following treatment with mitomycin C or doxorubicin. (A) Plates were treated with mitomycin C at the indicated concentrations. Each treatment was done in triplicate and averages and standard deviations are shown. To reduce overlap of the symbols in the charts, the symbols representing different cell lines at the same treatment dosage were slightly horizontally offset. No  $Ubr2^{-/-}$  or  $+/+$  MEFs survived exposure to 0.4  $\mu$ M mitomycin C. (B)  $Ubr2^{-/-}$  and  $+/+$  MEFs were treated with doxorubicin at indicated concentrations, and the survival of cells was determined by MTT assay [33] (see Section 2). Percent survival of each treatment was calculated by dividing the absorbance value of untreated cells. All treatments were triplicated.




Fig. 4. Homologous recombination mediated double strand break repair is deficient in *Ubr2*<sup>-/-</sup> cells according to an I-*SceI*-based assay [34]. (A) Identification of *Ubr2*<sup>-/-</sup> and +/+ MEF cells that reconstituted GFP expression using flow cytometry. For each plot, the cells represented to the right of each diagonal line expressed GFP, while cells represented to the left of this line were considered negative for GFP expression. (B) Multiple independently derived *Ubr2*<sup>-/-</sup> cell lines display reduced HR DSB repair. Flow cytometry results were obtained for seven independently derived cell lines. Averages and standard deviations of three repetitions of the procedure are shown. The GFP expression obtained for the +/+ reporter cell line 1 was arbitrarily assigned a value of 100 and the values obtained for the other six reporter lines are in relation to this value.

increased resistance to doxorubicin [67–69]. To determine whether *Ubr2*<sup>-/-</sup> cells display resistance to doxorubicin, *Ubr2*<sup>-/-</sup> and +/+ cells were treated with increasing concentrations of doxorubicin. In contrast to the reports for MMR mutants, the *Ubr2*<sup>-/-</sup> cells were not less sensitive to doxorubicin than +/+ cells (Fig. 3B). In fact, the *Ubr2*<sup>-/-</sup> cells were significantly more sensitive to doxorubicin ( $P > 0.0001$  using a General Linear Model).

#### 3.4. *Ubr2*<sup>-/-</sup> cells are defective in homologous recombination mediated double strand break repair

Direct measurements of DSB HR repair using I-*SceI* nuclease-based assays revealed that deficiencies in the HR genes *Xrcc2* and *Xrcc3* produce severe (>25-fold) reductions in HR repair [35,58] while loss of FA gene function has been associated with mild (<3.5-fold) reductions in the efficiency of HR repair [70–72]. To determine whether *Ubr2* is involved in HR repair, we subjected *Ubr2*<sup>-/-</sup> cells to an assay that generates a functional GFP gene via the HR repair of a DSB generated using I-*SceI* [34]. In wild type (+/+) cells with a normal capacity for HR repair, the double strand breaks were repaired, resulting in GFP expression that was readily identifiable using flow cytometry. In contrast, the introduction of vector plasmid resulted in much lower levels of GFP-expressing cells (Fig. 4A). The number of GFP-expressing cells was, on average, approximately 12 times lower in *Ubr2*<sup>-/-</sup> MEFs upon I-*SceI* expression compared to +/+ cells (Fig. 4A and B), a highly significant difference according to the

Kruskal–Wallis test ( $P = 1.92 \times 10^{-6}$ ) [37]. This indicated that DSB HR repair is compromised in *Ubr2*<sup>-/-</sup> cells. It should be pointed out that this assay did not distinguish single strand anneal (SSA) from the classical HR repair.

#### 4. Discussion

Various properties of *Ubr2*<sup>-/-</sup> MEFs were surveyed in order to determine whether the mouse *Ubr2* ubiquitin ligase plays a role in maintaining genome stability and/or DNA repair. Primary *Ubr2*<sup>-/-</sup> MEFs displayed an elevated incidence of micronuclei and nucleoplasmic bridges in the absence of exogenous agents. *Ubr2*<sup>-/-</sup> MEFs also exhibited high frequencies of spontaneous gaps or breaks in metaphase chromosomes, indicating chromosomal fragility. Similar to fragile sites in human cells [49–52], the chromosomal breaks and gaps in mouse *Ubr2*<sup>-/-</sup> chromosomes correlated with late replication in S phase. *Ubr2*<sup>-/-</sup> MEFs failed to display hypersensitivity to IR, appeared normal for NHEJ, and did not display resistance to doxorubicin, a trait associated with defects in MMR genes [67–69,73]. However, *Ubr2*<sup>-/-</sup> cells were hypersensitive to the DNA cross-linking agent mitomycin C and displayed a pronounced defect in HR repair.

The *Ubr2*<sup>-/-</sup> phenotype resembled the phenotypes brought on by defects in the five Rad51 paralogs, but appeared to be somewhat milder. Like *Ubr2*, the Rad51 paralogs are not essential for cell viability [21], but mouse knockouts of paralogs (*Xrcc2* [74], *Rad51B* [75], and *Rad51D* [76]) display embryonic lethality. All par-

alogs appear to be very important for HR repair [21]. The, on average, 12-fold reduction in HR repair of I-*SceI* sites in *Ubr2*<sup>-/-</sup> MEFs was less severe than the >100-fold and 25-fold reductions in HR repair of I-*SceI* sites reported for hamster cells defective in *Xrcc2* [58] and *Xrcc3* [35], respectively. BCCIP, like the paralogs, interacts with Rad51 and also causes >20-fold reductions in HR repair [77]. It is possible that the loss of one or more of the six other Ubr proteins will produce a HR repair defect that is as severe as in paralog-deficient cells. Similar to *Ubr2*<sup>-/-</sup> MEFs, paralog-deficient cells exhibit spontaneous gaps or breaks [56,57,60,62–64], are hypersensitive to mitomycin C [21], and intact for NHEJ [21]. Paralog-deficient cells are only slightly sensitive to IR [21]. The precise roles of the paralogs in HR and HR repair have not been thoroughly determined [21].

The *Ubr2*<sup>-/-</sup> phenotype also bears some resemblance to mutations in the FA-ATR-BRCA1 pathway that responds to DNA cross-links. I-*SceI*-based assays reveal mild reductions in DSB HR-repair in FA cells (<3.5-fold) [70–72] and *BRCA1*-deficient cells (five- to six-fold) [78]. However, *BRCA2*-deficient cells exhibited a 6–100-fold decrease, depending on the cell line [34]. Similar to *Ubr2* mutants, FA, *BRCA2*-deficient, *BRCA1*-deficient, and ATR-deficient cells are all sensitive to mitomycin C [22,79,80] but competent in NHEJ [22,34,71,78,80]. Finally, elevated frequencies of micronuclei, nucleoplasmic bridges, and gaps or breaks in spreads are associated with deficiencies in the FA-ATR-BRCA1 pathway [41,65,81–83]. It has been proposed that fragile sites are regions of the genome where DNA replication forks stall or collapse leading to late replication [51,84,85]. It was further proposed that a subset of these unreplicated single stranded regions escape checkpoint controls and proceed into mitosis where they break or stretch during the preparation of spreads [65,81,82]. The late replication at the spontaneous gaps or breaks in *Ubr2*<sup>-/-</sup> chromosomes and the associated HR repair defect are consistent with this hypothesis.

*Ubr2* joins a list of ubiquitin and SUMO E3 ligases that have been implicated in HR repair. Monoubiquitylation of FANCD2 is considered a central event in the response to DNA cross-links and requires several proteins in the FA-ATR-BRCA1 pathway [22,86,87] including the ubiquitin ligase FANCL [23]. Ubiquitylated FANCD2 co-localizes [88] with the ubiquitin ligase BRCA1 [89–93] which ubiquitinylates FANCD2 in vitro [94]. Another example is the ubiquitin-mediated proteolysis of Rad51 via an unidentified ligase that is regulated by RAD51C [95]. Rad51 also interacts with unconjugated SUMO and over-expression of wild type

SUMO or an unconjugatable mutant SUMO inhibits HR repair [96]. Finally, the DNA replication protein PCNA is modified by SUMO [97] and this suppresses HR during S phase, perhaps to prevent unwanted HR repair [98].

The mechanisms that underlie the *Ubr2*-dependent maintenance of genome integrity and HR repair are unknown. Although we recently found that *Ubr2* (and a related protein *Ubr1*) ubiquitylate RGS4, RGS5, and RGS16, failure to degrade these proteins is unlikely to be responsible for the genome stability and DNA repair defects of *Ubr2*<sup>-/-</sup> cells, given that the function of the RGS proteins is to control extracellular stimulus-mediated signaling pathways [10,11]. Proteins that are more likely to mediate *Ubr2*'s role in genome stability and HR repair include Recq14 and Scc1. We have recently found that human *Ubr2* and *Ubr1* form a complex with Recq14 [99], a putative helicase that is mutated in both Rothmund–Thomson syndrome (RTS) [100,101] and RAPADILINO syndrome [102]. Cells from RTS patients display chromosomal instability [103,104], suggesting that a disrupted *Ubr1–Ubr2–Recq14* circuit may contribute to the genome instability of *Ubr2*<sup>-/-</sup> mouse cells. Scc1 is a subunit of the cohesin complex that is recruited to DSBs during HR repair [19]. Conditional cleavage of fission yeast SCC1 by a protease called separase has been shown to be required for DNA repair [105]. In budding yeast, one of the SCC1 cleavage products has been shown to be degraded by yeast UBR1 [106], a homolog of mouse *Ubr2* [1]. Disruption of this degradation results in chromosome loss that is likely due to the perturbation of cohesin function by the SCC1 fragment [106]. In mice, *Ubr2*-deficiency may therefore alter cohesin function resulting in genome fragility and a HR repair defect. Future work will address whether *Ubr2* is involved in both SSA and classical HR repair, whether other Ubr ligases are involved, and whether the role of *Ubr2* in HR repair and the prevention of chromosomal fragility are linked to interactions with Rad51, Rad51 paralogs, Recq14, and cohesin.

## Acknowledgements

We would like to thank Robert Schiestl (UCLA Department of Radiation Oncology) and Alexander Varshavsky (California Institute of Technology Division of Biology) for critically reading the manuscript. We also thank Rita Cantor (UCLA Department of Human Genetics) for help with the statistical analyses and Maria Jasin (Memorial Sloan-Kettering Cancer Center) for p59xDR-GFP6 and pCBASce. This work was supported by the National Institutes of Health

508 R01 HD41451:01 (Y.M.), R01 GM61007-01A1 (Y.M.),  
 509 R01 GM69482 (Y.T.K.), R01GM073981 (M.A.T.),  
 510 R01CA74929 (M.A.T.), R01CA107300 (M.A.T.), and  
 511 CMISE, a NASA URETI Institute (NCC 2-1364:  
 512 M.A.T.). M.A.T. is a Scholar of the Leukemia and Lym-  
 513 phoma Society.

## 514 References

- 515 [1] T. Tasaki, L.C. Mulder, A. Iwamatsu, M.J. Lee, I.V. Davydov, A.  
 516 Varshavsky, M. Muesing, Y.T. Kwon, A family of mammalian  
 517 E3 ubiquitin ligases that contain the UBR box motif and recog-  
 518 nize N-degrons, *Mol. Cell Biol.* 25 (2005) 7120–7136.
- 519 [2] Y.T. Kwon, Z. Xia, I.V. Davydov, S.H. Lecker, A. Varshavsky,  
 520 Construction and analysis of mouse strains lacking the ubiquitin  
 521 ligase UBR1 (E3alpha) of the N-end rule pathway, *Mol. Cell*  
 522 *Biol.* 21 (2001) 8007–8021.
- 523 [3] Y.T. Kwon, Z. Xia, J.Y. An, T. Tasaki, I.V. Davydov, J.W. Seo,  
 524 J. Sheng, Y. Xie, A. Varshavsky, Female lethality and apoptosis  
 525 of spermatocytes in mice lacking the UBR2 ubiquitin ligase  
 526 of the N-end rule pathway, *Mol. Cell Biol.* 23 (2003) 8255–  
 527 8271.
- 528 [4] A. Hershko, A. Ciechanover, The ubiquitin system for protein  
 529 degradation, *Annu. Rev. Biochem.* 61 (1992) 761–807.
- 530 [5] C.M. Pickart, M.J. Eddins, Ubiquitin: structures, functions,  
 531 mechanisms, *Biochim. Biophys. Acta* 1695 (2004) 55–72.
- 532 [6] A. Varshavsky, Regulated protein degradation, *Trends Biochem.*  
 533 *Sci.* 30 (2005) 283–286.
- 534 [7] A. Varshavsky, The N-end rule: functions, mysteries, uses, *Proc.*  
 535 *Natl. Acad. Sci. U.S.A.* 93 (1996) 12142–12149.
- 536 [8] V. Chau, J.W. Tobias, A. Bachmair, D. Marriott, D.J. Ecker,  
 537 D.K. Gonda, A. Varshavsky, A multiubiquitin chain is confined  
 538 to specific lysine in a targeted short-lived protein, *Science* 243  
 539 (1989) 1576–1583.
- 540 [9] E.S. Johnson, D.K. Gonda, A. Varshavsky, *cis-trans* recognition  
 541 and subunit-specific degradation of short-lived proteins, *Nature*  
 542 346 (1990) 287–291.
- 543 [10] R.G. Hu, J. Sheng, X. Qi, Z. Xu, T.T. Takahashi, A. Varshavsky,  
 544 The N-end rule pathway as a nitric oxide sensor controlling the  
 545 levels of multiple regulators, *Nature* 437 (2005) 981–986.
- 546 [11] M.J. Lee, T. Tasaki, K. Moroi, J.Y. An, S. Kimura, I.V. Davydov,  
 547 Y.T. Kwon, RGS4 and RGS5 are *in vivo* substrates of the N-  
 548 end rule pathway, *Proc. Natl. Acad. Sci. U.S.A.* 102 (2005)  
 549 15030–15035.
- 550 [12] C. Richardson, N. Horikoshi, T.K. Pandita, The role of the DNA  
 551 double-strand break response network in meiosis, *DNA Repair*  
 552 *(Amst.)* 3 (2004) 1149–1164.
- 553 [13] S.M. Baker, C.E. Bronner, L. Zhang, A.W. Plug, M. Robatzek,  
 554 G. Warren, E.A. Elliott, J. Yu, T. Ashley, N. Arnheim, R.A.  
 555 Flavell, R.M. Liskay, Male mice defective in the DNA mismatch  
 556 repair gene PMS2 exhibit abnormal chromosome synapsis in  
 557 meiosis, *Cell* 82 (1995) 309–319.
- 558 [14] G. Hamer, H.B. Kal, C.H. Westphal, T. Ashley, D.G. de Rooij,  
 559 Ataxia telangiectasia mutated expression and activation in the  
 560 testis, *Biol. Reprod.* 70 (2004) 1206–1212.
- 561 [15] Y. Xu, T. Ashley, E.E. Brainerd, R.T. Bronson, M.S. Meyn, D.  
 562 Baltimore, Targeted disruption of ATM leads to growth retar-  
 563 dation, chromosomal fragmentation during meiosis, immune  
 564 defects, and thymic lymphoma, *Genes Dev.* 10 (1996)  
 565 2411–2422.
- [16] A. Elson, Y. Wang, C.J. Daugherty, C.C. Morton, F. Zhou, 566  
 J. Campos-Torres, P. Leder, Pleiotropic defects in ataxia- 567  
 telangiectasia protein-deficient mice, *Proc. Natl. Acad. Sci.* 568  
*U.S.A.* 93 (1996) 13084–13089. 569
- [17] C. Barlow, S. Hirotsune, R. Paylor, M. Liyanage, M. Eckhaus, F. 570  
 Collins, Y. Shiloh, J.N. Crawley, T. Ried, D. Tagle, A. Wynshaw- 571  
 Boris, Atm-deficient mice: a paradigm of ataxia telangiectasia, 572  
*Cell* 86 (1996) 159–171. 573
- [18] G. Hamer, H.L. Roepers-Gajadien, A. van Duyn-Goedhart, I.S. 574  
 Gademan, H.B. Kal, P.P. van Buul, T. Ashley, D.G. de Rooij, 575  
 Function of DNA-protein kinase catalytic subunit during the 576  
 early meiotic prophase without Ku70 and Ku86, *Biol. Reprod.* 577  
 68 (2003) 717–721. 578
- [19] A. Losada, T. Hirano, Dynamic molecular linkers of the genome: 579  
 the first decade of SMC proteins, *Genes Dev.* 19 (2005) 580  
 1269–1287. 581
- [20] K. Valerie, L.F. Povirk, Regulation and mechanisms of 582  
 mammalian double-strand break repair, *Oncogene* 22 (2003) 583  
 5792–5812. 584
- [21] M. Kawabata, T. Kawabata, M. Nishibori, Role of recA/RAD51 585  
 family proteins in mammals, *Acta Med. Okayama* 59 (2005) 586  
 1–9. 587
- [22] A.D. D'Andrea, M. Grompe, The Fanconi anaemia/BRCA path- 588  
 way, *Nat. Rev. Cancer* 3 (2003) 23–34. 589
- [23] A.R. Meetei, J.P. de Winter, A.L. Medhurst, M. Wallisch, Q. 590  
 Waisfisz, H.J. van de Vrugt, A.B. Oostra, Z. Yan, C. Ling, C.E. 591  
 Bishop, M.E. Hoatlin, H. Joenje, W. Wang, A novel ubiquitin 592  
 ligase is deficient in Fanconi anemia, *Nat. Genet.* 35 (2003) 593  
 165–170. 594
- [24] P. Pichierri, F. Rosselli, The DNA crosslink-induced S-phase 595  
 checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 596  
 pathways, *EMBO J.* 23 (2004) 1178–1187. 597
- [25] S. Houghtaling, C. Timmers, M. Noll, M.J. Finegold, S.N. Jones, 598  
 M.S. Meyn, M. Grompe, Epithelial cancer in Fanconi anemia 599  
 complementation group D2 (Fancd2) knockout mice, *Genes* 600  
*Dev.* 17 (2003) 2021–2035. 601
- [26] M. Noll, K.P. Battaile, R. Bateman, T.P. Lax, K. Rathbun, C. 602  
 Reifsteck, G. Bagby, M. Finegold, S. Olson, M. Grompe, Fan- 603  
 conic anemia group A and C double-mutant mice: functional 604  
 evidence for a multi-protein Fanconi anemia complex, *Exp.* 605  
*Hematol.* 30 (2002) 679–688. 606
- [27] N.C. Cheng, H.J. van de Vrugt, M.A. van der Valk, A.B. Oostra, 607  
 P. Krimpenfort, Y. de Vries, H. Joenje, A. Berns, F. Arwert, Mice 608  
 with a targeted disruption of the Fanconi anemia homolog Fanca, 609  
*Hum. Mol. Genet.* 9 (2000) 1805–1811. 610
- [28] M. Chen, D.J. Tomkins, W. Auerbach, C. McKerlie, H. Yous- 611  
 soufian, L. Liu, O. Gan, M. Carreau, A. Auerbach, T. Groves, 612  
 C.J. Guidos, M.H. Freedman, J. Cross, D.H. Percy, J.E. Dick, 613  
 A.L. Joyner, M. Buchwald, Inactivation of Fac in mice produces 614  
 inducible chromosomal instability and reduced fertility reminis- 615  
 cent of Fanconi anaemia, *Nat. Genet.* 12 (1996) 448–451. 616
- [29] Y. Yang, Y. Kuang, R.M. De Oca, T. Hays, L. Moreau, N. Lu, 617  
 B. Seed, A.D. D'Andrea, Targeted disruption of the murine 618  
 Fanconi anemia gene, *Fancg/Xrcc9*, *Blood* 98 (2001) 3435– 619  
 3440. 620
- [30] R. Scully, D.M. Livingston, In search of the tumour-suppressor 621  
 functions of BRCA1 and BRCA2, *Nature* 408 (2000) 429– 622  
 432. 623
- [31] P.S. Jat, C.L. Cepko, R.C. Mulligan, P.A. Sharp, Recombinant 624  
 retroviruses encoding simian virus 40 large T antigen and poly- 625  
 omavirus large and middle T antigens, *Mol. Cell Biol.* 6 (1986) 626  
 1204–1217. 627

- 628 [32] S. Diaz-Perez, Y. Ouyang, V. Perez, R. Cisneros, M. Regelson, 690  
629 Y. Marahrens, Element(s) at the non-transcribed Xist locus of the 691  
630 active X chromosome control chromosomal replication timing 692  
631 in the mouse, *Genetics* (2005). 693
- 632 [33] T. Mosmann, Rapid colorimetric assay for cellular growth and 694  
633 survival: application to proliferation and cytotoxicity assays, *J.* 695  
634 *Immunol. Methods* 65 (1983) 55–63. 696
- 635 [34] M.E. Moynahan, A.J. Pierce, M. Jasin, BRCA2 is required for 697  
636 homology-directed repair of chromosomal breaks, *Mol. Cell* 7 698  
637 (2001) 263–272. 699
- 638 [35] A.J. Pierce, R.D. Johnson, L.H. Thompson, M. Jasin, XRCC3 700  
639 promotes homology-directed repair of DNA damage in mam- 701  
640 malian cells, *Genes Dev.* 13 (1999) 2633–2638. 702
- 641 [36] R. Ihaka, R. Gentleman, R: a language for data analysis and 703  
642 graphics, *J. Comput. Graphical Stat.* 5 (1996) 299–314. 704
- 643 [37] J.B. Kruskal, Multidimensional scaling by optimizing good- 705  
644 ness of fit to a nonmetric hypothesis, *Psychometrika* 29 (1964) 706  
645 1–27. 707
- 646 [38] A. Sancar, L.A. Lindsey-Boltz, K. Unsal-Kacmaz, S. Linn, 708  
647 Molecular mechanisms of mammalian DNA repair and the DNA 709  
648 damage checkpoints, *Annu. Rev. Biochem.* 73 (2004) 39–85. 710
- 649 [39] E.B. Kabotyanski, L. Gomelsky, J.O. Han, T.D. Stamato, 711  
650 D.B. Roth, Double-strand break repair in Ku86- and XRCC4- 712  
651 deficient cells, *Nucleic Acids Res.* 26 (1998) 5333–5342. 713
- 652 [40] J. Smith, E. Riballo, B. Kysela, C. Baldeyron, K. Manolis, C. 714  
653 Masson, M.R. Lieber, D. Papadopoulo, P. Jeggo, Impact of DNA 715  
654 ligase IV on the fidelity of end joining in human cells, *Nucleic 716  
655 Acids Res.* 31 (2003) 2157–2167. 717
- 656 [41] S.W. Maluf, B. Erdtmann, Genomic instability in Down syn- 718  
657 drome and Fanconi anemia assessed by micronucleus analysis 719  
658 and single-cell gel electrophoresis, *Cancer Genet. Cytogenet.* 720  
659 124 (2001) 71–75. 721
- 660 [42] S. Ban, T. Shinohara, Y. Hirai, Y. Moritaku, J.B. Cologne, D.G. 722  
661 MacPhee, Chromosomal instability in BRCA1- or BRCA2- 723  
662 defective human cancer cells detected by spontaneous micronu- 724  
663 cleus assay, *Mutat. Res.* 474 (2001) 15–23. 725
- 664 [43] G.K. Alderton, H. Joenje, R. Varon, A.D. Borglum, P.A. 726  
665 Jeggo, M. O'Driscoll, Seckel syndrome exhibits cellular fea- 727  
666 tures demonstrating defects in the ATR-signalling pathway, 728  
667 *Hum. Mol. Genet.* 13 (2004) 3127–3138. 729
- 668 [44] S. Gutierrez-Enriquez, J. Hall, Use of the cytokinesis-block 730  
669 micronucleus assay to measure radiation-induced chromosome 731  
670 damage in lymphoblastoid cell lines, *Mutat. Res.* 535 (2003) 732  
671 1–13. 733
- 672 [45] T.L. Kojis, R.R. Schreck, R.A. Gatti, R.S. Sparkes, Tissue speci- 734  
673 ficity of chromosomal rearrangements in ataxia-telangiectasia, 735  
674 *Hum. Genet.* 83 (1989) 347–352. 736
- 675 [46] T.L. Kojis, R.A. Gatti, R.S. Sparkes, The cytogenetics of 737  
676 ataxia telangiectasia, *Cancer Genet. Cytogenet.* 56 (1991) 143– 738  
677 156. 739
- 678 [47] M. Fenech, J.W. Crott, Micronuclei, nucleoplasmic bridges 740  
679 and nuclear buds induced in folic acid deficient human 741  
680 lymphocytes-evidence for breakage-fusion-bridge cycles in the 742  
681 cytokinesis-block micronucleus assay, *Mutat. Res.* 504 (2002) 743  
682 131–136. 744
- 683 [48] P. Thomas, K. Umegaki, M. Fenech, Nucleoplasmic bridges 745  
684 are a sensitive measure of chromosome rearrangement in the 746  
685 cytokinesis-block micronucleus assay, *Mutagenesis* 18 (2003) 747  
686 187–194. 748
- 687 [49] R.S. Hansen, T.K. Canfield, M.M. Lamb, S.M. Gartler, C.D. 749  
688 Laird, Association of fragile X syndrome with delayed replica- 750  
689 tion of the FMR1 gene, *Cell* 73 (1993) 1403–1409. 751
- [50] L. Wang, J. Darling, J.S. Zhang, H. Huang, W. Liu, D. Smith, 690  
Allele-specific late replication and fragility of the most active 691  
common fragile site, FRA3B, *Hum. Mol. Genet.* 8 (1999) 692  
431–437. 693
- [51] A. Hellman, A. Rahat, S.W. Scherer, A. Darvasi, L.C. Tsui, 694  
B. Kerem, Replication delay along FRA7H, a common fragile 695  
site on human chromosome 7, leads to chromosomal instability, 696  
*Mol. Cell Biol.* 20 (2000) 4420–4427. 697
- [52] M.F. Arlt, A.M. Casper, T.W. Glover, Common fragile sites, 698  
*Cytogenet. Genome Res.* 100 (2003) 92–100. 699
- [53] B.C. Turner, M. Ottey, D.B. Zimonjic, M. Potoczek, W.W. 700  
Hauck, E. Pequignot, C.L. Keck-Waggoner, C. Sevignani, C.M. 701  
Aldaz, P.A. McCue, J. Palazzo, K. Huebner, N.C. Popescu, 702  
The fragile histidine triad/common chromosome fragile site 3B 703  
locus and repair-deficient cancers, *Cancer Res.* 62 (2002) 4054– 704  
4060. 705
- [54] S. Fiumicino, S. Martinelli, C. Colussi, G. Aquilina, C. Leonetti, 706  
M. Crescenzi, M. Bignami, Sensitivity to DNA cross-linking 707  
chemotherapeutic agents in mismatch repair-defective cells in 708  
vitro and in xenografts, *Int. J. Cancer* 85 (2000) 590–596. 709
- [55] K. Caldecott, P. Jeggo, Cross-sensitivity of gamma-ray-sensitive 710  
hamster mutants to cross-linking agents, *Mutat. Res.* 255 (1991) 711  
111–121. 712
- [56] B. Deans, C.S. Griffin, P. O'Regan, M. Jasin, J. Thacker, Homol- 713  
ogous recombination deficiency leads to profound genetic insta- 714  
bility in cells derived from *Xrcc2*-knockout mice, *Cancer Res.* 715  
63 (2003) 8181–8187. 716
- [57] L.F. Fuller, R.B. Painter, A Chinese hamster ovary cell line 717  
hypersensitive to ionizing radiation and deficient in repair repli- 718  
cation, *Mutat. Res.* 193 (1988) 109–121. 719
- [58] R.D. Johnson, N. Liu, M. Jasin, Mammalian XRCC2 promotes 720  
the repair of DNA double-strand breaks by homologous recom- 721  
bination, *Nature* 401 (1999) 397–399. 722
- [59] N.J. Jones, R. Cox, J. Thacker, Isolation and cross-sensitivity 723  
of X-ray-sensitive mutants of V79-4 hamster cells, *Mutat. Res.* 724  
183 (1987) 279–286. 725
- [60] N. Liu, J.E. Lamerdin, R.S. Tebbs, D. Schild, J.D. Tucker, M.R. 726  
Shen, K.W. Brookman, M.J. Siciliano, C.A. Walter, W. Fan, 727  
L.S. Narayana, Z.Q. Zhou, A.W. Adamson, K.J. Sorensen, D.J. 728  
Chen, N.J. Jones, L.H. Thompson, XRCC2 and XRCC3, new 729  
human Rad51-family members, promote chromosome stability 730  
and protect against DNA cross-links and other damages, *Mol.* 731  
*Cell* 1 (1998) 783–793. 732
- [61] M.S. Sasaki, M. Takata, E. Sonoda, A. Tachibana, S. Takeda, 733  
Recombination repair pathway in the maintenance of chromo- 734  
somal integrity against DNA interstrand crosslinks, *Cytogenet.* 735  
*Genome Res.* 104 (2004) 28–34. 736
- [62] P.G. Smiraldo, A.M. Gruver, J.C. Osborn, D.L. Pittman, Exten- 737  
sive chromosomal instability in Rad51d-deficient mouse cells, 738  
*Cancer Res.* 65 (2005) 2089–2096. 739
- [63] M. Takata, M.S. Sasaki, S. Tachiiri, T. Fukushima, E. Sonoda, 740  
D. Schild, L.H. Thompson, S. Takeda, Chromosome instabil- 741  
ity and defective recombinational repair in knockout mutants 742  
of the five Rad51 paralogs, *Mol. Cell Biol.* 21 (2001) 2858– 743  
2866. 744
- [64] R.S. Tebbs, Y. Zhao, J.D. Tucker, J.B. Scheerer, M.J. Siciliano, 745  
M. Hwang, N. Liu, R.J. Legerski, L.H. Thompson, Correction 746  
of chromosomal instability and sensitivity to diverse mutagens 747  
by a cloned cDNA of the XRCC3 DNA repair gene, *Proc. Natl.* 748  
*Acad. Sci. U.S.A.* 92 (1995) 6354–6358. 749
- [65] N.G. Howlett, T. Taniguchi, S.G. Durkin, A.D. D'Andrea, 750  
T.W. Glover, The Fanconi anemia pathway is required for the 751

- 752 DNA replication stress response and for the regulation of com-  
753 mon fragile site stability, *Hum. Mol. Genet.* 14 (2005) 693–  
754 701.
- 755 [66] J.B. Wilson, M.A. Johnson, A.P. Stuckert, K.L. Trueman, S.  
756 May, P.E. Bryant, R.E. Meyn, A.D. D'Andrea, N.J. Jones, The  
757 Chinese hamster FANCG/XRCC9 mutant NM3 fails to express  
758 the monoubiquitinated form of the FANCD2 protein, is hyper-  
759 sensitive to a range of DNA damaging agents and exhibits a  
760 normal level of spontaneous sister chromatid exchange, *Carcinogenesis* 22 (2001) 1939–1946.  
761
- 762 [67] H. Lage, M. Dietel, Involvement of the DNA mismatch repair  
763 system in antineoplastic drug resistance, *J. Cancer Res. Clin.*  
764 *Oncol.* 125 (1999) 156–165.
- 765 [68] A. Fedier, V.A. Schwarz, H. Walt, R.D. Carpini, U. Haller,  
766 D. Fink, Resistance to topoisomerase poisons due to loss  
767 of DNA mismatch repair, *Int. J. Cancer* 93 (2001) 571–  
768 576.
- 769 [69] S.T. Durant, M.M. Morris, M. Illand, H.J. McKay, C.  
770 McCormick, G.L. Hirst, R.H. Borts, R. Brown, Dependence  
771 on RAD52 and RAD1 for anticancer drug resistance mediated  
772 by inactivation of mismatch repair genes, *Curr. Biol.* 9 (1999)  
773 51–54.
- 774 [70] Y.G. Yang, Z. Herceg, K. Nakanishi, I. Demuth, C. Piccoli, J.  
775 Michelson, G. Hildebrand, M. Jasin, M. Digweed, Z.Q. Wang,  
776 The Fanconi anemia group A protein modulates homologous  
777 repair of DNA double-strand breaks in mammalian cells, *Carcinogenesis* (2005).  
778
- 779 [71] K. Nakanishi, Y.G. Yang, A.J. Pierce, T. Taniguchi, M. Dig-  
780 weed, A.D. D'Andrea, Z.Q. Wang, M. Jasin, Human Fanconi  
781 anemia monoubiquitination pathway promotes homologous  
782 DNA repair, *Proc. Natl. Acad. Sci. U.S.A.* 102 (2005) 1110–  
783 1115.
- 784 [72] W. Niedzwiedz, G. Mosedale, M. Johnson, C.Y. Ong, P. Pace,  
785 K.J. Patel, The Fanconi anaemia gene FANCC promotes homol-  
786 ogous recombination and error-prone DNA repair, *Mol. Cell* 15  
787 (2004) 607–620.
- 788 [73] A. Bellacosa, Functional interactions and signaling properties of  
789 mammalian DNA mismatch repair proteins, *Cell Death Differ.*  
790 8 (2001) 1076–1092.
- 791 [74] B. Deans, C.S. Griffin, M. Maconochie, J. Thacker, *Xrcc2* is  
792 required for genetic stability, embryonic neurogenesis and vi-  
793 ability in mice, *EMBO J.* 19 (2000) 6675–6685.
- 794 [75] Z. Shu, S. Smith, L. Wang, M.C. Rice, E.B. Kmiec, Disruption of  
795 *muREC2/RAD51L1* in mice results in early embryonic lethality  
796 which can be partially rescued in a *p53*( $-/-$ ) background, *Mol.*  
797 *Cell Biol.* 19 (1999) 8686–8693.
- 798 [76] D.L. Pittman, J.C. Schimenti, Midgestation lethality in mice  
799 deficient for the RecA-related gene, *Rad51d/Rad51l3*, *Genesis*  
800 26 (2000) 167–173.
- 801 [77] H. Lu, X. Guo, X. Meng, J. Liu, C. Allen, J. Wray, J.A.  
802 Nickoloff, Z. Shen, The BRCA2-interacting protein BCCIP  
803 functions in RAD51 and BRCA2 focus formation and homol-  
804 ogous recombinational repair, *Mol. Cell Biol.* 25 (2005) 1949–  
805 1957.
- 806 [78] M.E. Moynahan, J.W. Chiu, B.H. Koller, M. Jasin, *Brc1*  
807 controls homology-directed DNA repair, *Mol. Cell* 4 (1999)  
808 511–518.
- 809 [79] J. Yun, Q. Zhong, J.Y. Kwak, W.H. Lee, Hypersensitivity of  
810 *Brc1*-deficient MEF to the DNA interstrand crosslinking agent  
811 mitomycin C is associated with defect in homologous recombi-  
812 nation repair and aberrant S-phase arrest, *Oncogene* 24 (2005)  
813 4009–4016.
- [80] H. Wang, H. Wang, S.N. Powell, G. Iliakis, Y. Wang, ATR affect- 814  
ing cell radiosensitivity is dependent on homologous recombi- 815  
nation repair but independent of nonhomologous end joining, 816  
*Cancer Res.* 64 (2004) 7139–7143. 817
- [81] A.M. Casper, P. Nghiem, M.F. Arlt, T.W. Glover, ATR regulates 818  
fragile site stability, *Cell* 111 (2002) 779–789. 819
- [82] M.F. Arlt, B. Xu, S.G. Durkin, A.M. Casper, M.B. Kastan, T.W. 820  
Glover, BRCA1 is required for common-fragile-site stability 821  
via its G2/M checkpoint function, *Mol. Cell Biol.* 24 (2004) 822  
6701–6709. 823
- [83] G. Speit, K. Trenz, Chromosomal mutagen sensitivity associated 824  
with mutations in BRCA genes, *Cytogenet. Genome Res.* 104 825  
(2004) 325–332. 826
- [84] M.M. Le Beau, F.V. Rassool, M.E. Neilly, R. Espinosa III, 827  
T.W. Glover, D.I. Smith, T.W. McKeithan, Replication of a 828  
common fragile site, FRA3B, occurs late in S phase and is 829  
delayed further upon induction: implications for the mecha- 830  
nism of fragile site induction, *Hum. Mol. Genet.* 7 (1998) 755– 831  
761. 832
- [85] C. Laird, E. Jaffe, G. Karpen, M. Lamb, R. Nelson, Fragile 833  
sites in human chromosomes as regions of late-replicating DNA, 834  
*Trends Genet.* 3 (1987) 274–281. 835
- [86] X. Wang, A.D. D'Andrea, The interplay of Fanconi anemia 836  
proteins in the DNA damage response, *DNA Repair (Amst.)* 3 837  
(2004) 1063–1069. 838
- [87] L.H. Thompson, Unraveling the Fanconi anemia–DNA repair 839  
connection, *Nat. Genet.* 37 (2005) 921–922. 840
- [88] I. Garcia-Higuera, T. Taniguchi, S. Ganesan, M.S. Meyn, C. 841  
Timmers, J. Hejna, M. Grompe, A.D. D'Andrea, Interaction of the 842  
Fanconi anemia proteins and BRCA1 in a common pathway, 843  
*Mol. Cell* 7 (2001) 249–262. 844
- [89] A. Chen, F.E. Kleiman, J.L. Manley, T. Ouchi, Z.Q. Pan, 845  
Autoubiquitination of the BRCA1\*BARD1 RING ubiquitin lig- 846  
ase, *J. Biol. Chem.* 277 (2002) 22085–22092. 847
- [90] Y. Dong, M.A. Hakimi, X. Chen, E. Kumaraswamy, N.S. 848  
Cooch, A.K. Godwin, R. Shiekhattar, Regulation of BRCC, 849  
a holoenzyme complex containing BRCA1 and BRCA2, by a 850  
signalosome-like subunit and its role in DNA repair, *Mol. Cell* 851  
12 (2003) 1087–1099. 852
- [91] K. Sato, R. Hayami, W. Wu, T. Nishikawa, H. Nishikawa, Y. 853  
Okuda, H. Ogata, M. Fukuda, T. Ohta, Nucleophosmin/B23 is 854  
a candidate substrate for the BRCA1–BARD1 ubiquitin ligase, 855  
*J. Biol. Chem.* 279 (2004) 30919–30922. 856
- [92] L.M. Starita, Y. Machida, S. Sankaran, J.E. Elias, K. Griffin, B.P. 857  
Schlegel, S.P. Gygi, J.D. Parvin, BRCA1-dependent ubiquitina- 858  
tion of gamma-tubulin regulates centrosome number, *Mol. Cell* 859  
Biol. 24 (2004) 8457–8466. 860
- [93] S. Sankaran, L.M. Starita, A.C. Groen, M.J. Ko, J.D. Parvin, 861  
Centrosomal microtubule nucleation activity is inhibited by 862  
BRCA1-dependent ubiquitination, *Mol. Cell Biol.* 25 (2005) 863  
8656–8668. 864
- [94] C.J. Vandenberg, F. Gergely, C.Y. Ong, P. Pace, D.L. Mallery, 865  
K. Hiom, K.J. Patel, BRCA1-independent ubiquitination of 866  
FANCD2, *Mol. Cell* 12 (2003) 247–254. 867
- [95] B.T. Bennett, K.L. Knight, Cellular localization of human 868  
*Rad51C* and regulation of ubiquitin-mediated proteolysis of 869  
*Rad51*, *J. Cell Biochem.* 96 (2005) 1095–1109. 870
- [96] W. Li, B. Hesabi, A. Babbo, C. Pacione, J. Liu, D.J. Chen, J.A. 871  
Nickoloff, Z. Shen, Regulation of double-strand break-induced 872  
mammalian homologous recombination by UBL1, a RAD51- 873  
interacting protein, *Nucleic Acids Res.* 28 (2000) 1145– 874  
1153. 875

- 876 [97] C. Hoege, B. Pfander, G.L. Moldovan, G. Pyrowolakis, S. 894  
877 Jentsch, RAD6-dependent DNA repair is linked to modification 895  
878 of PCNA by ubiquitin and SUMO, *Nature* 419 (2002) 135–141. 896  
879 [98] B. Pfander, G.L. Moldovan, M. Sacher, C. Hoege, S. Jentsch, 897  
880 SUMO-modified PCNA recruits Srs2 to prevent recombination 898  
881 during S phase, *Nature* 436 (2005) 428–433. 899  
882 [99] J. Yin, Y.T. Kwon, A. Varshavsky, W. Wang, RECQL4, mutated 900  
883 in the Rothmund–Thomson and RAPADILINO syndromes, 901  
884 interacts with ubiquitin ligases UBR1 and UBR2 of the N-end 902  
885 rule pathway, *Hum. Mol. Genet.* 13 (2004) 2421–2430. 903  
886 [100] S. Kitao, A. Shimamoto, M. Goto, R.W. Miller, W.A. Smithson, 904  
887 N.M. Lindor, Y. Furuichi, Mutations in RECQL4 cause a sub- 905  
888 set of cases of Rothmund–Thomson syndrome, *Nat. Genet.* 22 906  
889 (1999) 82–84. 907  
890 [101] N.M. Lindor, Y. Furuichi, S. Kitao, A. Shimamoto, C. Arndt, S. 908  
891 Jalal, Rothmund–Thomson syndrome due to RECQL4 helicase 909  
892 mutations: report and clinical and molecular comparisons with 910  
893 Bloom syndrome and Werner syndrome, *Am. J. Med. Genet.* 90 (2000) 223–228. 911
- [102] H.A. Siitonen, O. Kopra, H. Kaariainen, H. Haravuori, R.M. Winter, A.M. Saamanen, L. Peltonen, M. Kestila, Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases, *Hum. Mol. Genet.* 12 (2003) 2837–2844.
- [103] C.Z. Bachrati, I.D. Hickson, RecQ helicases: suppressors of tumorigenesis and premature aging, *Biochem. J.* 374 (2003) 577–606.
- [104] S.G. Grant, S.L. Wenger, J.J. Latimer, D. Thull, L.W. Burke, Analysis of genomic instability using multiple assays in a patient with Rothmund–Thomson syndrome, *Clin. Genet.* 58 (2000) 209–215.
- [105] K. Nagao, Y. Adachi, M. Yanagida, Separase-mediated cleavage of cohesin at interphase is required for DNA repair, *Nature* 430 (2004) 1044–1048.
- [106] H. Rao, F. Uhlmann, K. Nasmyth, A. Varshavsky, Degradation of a cohesin subunit by the N-end rule pathway is essential for chromosome stability, *Nature* 410 (2001) 955–959.

UNCORRECTED PROOF